Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial.

ABSTRACT:

Importance

The PCSK9 inhibitor evolocumab reduced major vascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, yet the types and sizes of myocardial outcomes in FOURIER have not been previously explored.

Objective

To assess the types and sizes of myocardial infarction (MI) and the effect of evolocumab on MI by subtype.

Design, setting, and participants

A prespecified analysis of a multicenter double-blind randomized clinical trial. Patients were randomized to evolocumab or placebo and followed up for a median of 2.2 years. The study included 27 564 patients with stable atherosclerotic disease receiving statin therapy. Clinical end points were evaluated by the Thrombolysis in Myocardial Infa

SUBMITTER: Wiviott SD 

PROVIDER: S-EPMC7191470 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature